The medtech industry faces unprecedented pressures. Among the biggest challenges, and the most urgent, companies must adapt to impending deadlines of the radically revised Euorpean regulatory environment.

These regulatory changes, which go into full effect in May 2020 for device manufacturers, and May 2022 for in vitro diagnostics manufacturers, have much broader reach and implications than for EU countries only. In parallel, the industry is contending with other changes that are upending established ways of working, from evolving market access, real-world evidence (RWE) and postmarket surveillance requirements, to the effect of US legislation on sales and service teams.

These hurdles have made two points very clear:

• Change is inevitable, and;
• No medtech company has the resources and expertise to address all challenges to meet its business needs and advance to operational excellence.

Download our Whitepaper “How Medtech is Responding To Changes Set To Reshape The Industry” now to learn more

Sponsored content from IQVIA